Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Biocept Inc

(NASDAQ: BIOC)
Add to Portfolio
-0.02 (-7.14%)
as of Dec 13, 2019

Last 0.26
Change -0.02 (-7.14%)
Open 0.28
Prev. Close 0.28
Today's Range
0.26
0.28
52wk Range
0.24
3.72
Volume 5,949,400
Avg Volume 3,920,530
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
BIOC -7.14% -66.59% -65.64%
DJIA +0.01% +7.38% +14.38%
S&P 500 +0.01% +8.87% +19.55%

Key Statistics

Annual EPS -2.67
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 6,390
Weighted Alpha -75.02
Standard Deviation -0.30
Profit Margin 3.63%
Beta 1.71

Growth Rates

YTD -69.23%
1-Year -67.73%
3-Year -99.02%
5-Year -99.90%

Opinion

Sell Hold Buy

Recent Headlines

Biocept Announces Closing of $10.0 Million

PR Newswire via COMTEX - Thu Dec 12, 08:00AM EST
Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced that on December 11, 2019 it closed its previously announced underwritten public offering of 24,6(full story)
BIOC: 0.26 (-0.02)

Biocept Announces Pricing of $10.0 Million

PR Newswire via COMTEX - Mon Dec 09, 09:15AM EST
Biocept, Inc. (NASDAQ: BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-f(full story)
BIOC: 0.26 (-0.02)

Biocept's Liquid Biopsy CTC Testing for Breast Cancer

PR Newswire via COMTEX - Tue Dec 03, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that cli(full story)
BIOC: 0.26 (-0.02)

Biocept Announces the Launch of its Liquid Biopsy Test

PR Newswire via COMTEX - Thu Nov 21, 08:05AM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the comm(full story)
BIOC: 0.26 (-0.02)

Biocept Reports Third Quarter 2019 Financial Results

PR Newswire via COMTEX - Wed Nov 13, 04:05PM EST
Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the(full story)
BIOC: 0.26 (-0.02)